MA42974A - Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer - Google Patents

Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer

Info

Publication number
MA42974A
MA42974A MA042974A MA42974A MA42974A MA 42974 A MA42974 A MA 42974A MA 042974 A MA042974 A MA 042974A MA 42974 A MA42974 A MA 42974A MA 42974 A MA42974 A MA 42974A
Authority
MA
Morocco
Prior art keywords
cancer
predicting
compositions
methods
therapeutic effectiveness
Prior art date
Application number
MA042974A
Other languages
English (en)
Inventor
Daniel Maurus
Ugur Sahin
Özlem Türeci
Original Assignee
Ganymed Pharmaceuticals Gmbh
Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Ggmbh Tron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Gmbh, Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Ggmbh Tron filed Critical Ganymed Pharmaceuticals Gmbh
Publication of MA42974A publication Critical patent/MA42974A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
MA042974A 2015-04-15 2016-04-13 Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer MA42974A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/058212 WO2016165765A1 (fr) 2015-04-15 2015-04-15 Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer

Publications (1)

Publication Number Publication Date
MA42974A true MA42974A (fr) 2018-08-22

Family

ID=52829110

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042974A MA42974A (fr) 2015-04-15 2016-04-13 Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer

Country Status (15)

Country Link
US (3) US10927413B2 (fr)
EP (1) EP3283644B1 (fr)
JP (3) JP6976855B2 (fr)
KR (2) KR102409933B1 (fr)
CN (1) CN107873061B (fr)
AU (1) AU2016249784B2 (fr)
CA (1) CA2982390A1 (fr)
ES (1) ES2787708T3 (fr)
HK (1) HK1246829A1 (fr)
IL (3) IL296503B2 (fr)
MA (1) MA42974A (fr)
MX (2) MX2017013074A (fr)
SG (1) SG11201708270YA (fr)
WO (2) WO2016165765A1 (fr)
ZA (1) ZA201705936B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016165765A1 (fr) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer
WO2016165762A1 (fr) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
CN108330180A (zh) * 2017-10-25 2018-07-27 广州和康医疗技术有限公司 一种对fcgr3a位点进行基因型检测的方法及试剂盒
WO2019144275A1 (fr) * 2018-01-23 2019-08-01 北京艾克伦医疗科技有限公司 Méthode et kit pour identifier l'état d'un cancer du poumon
MX2020009326A (es) 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
KR20220024010A (ko) * 2019-05-16 2022-03-03 치루 파머수티컬 컴퍼니 리미티드 클라우딘 18a2에 대한 항체 및 그의 용도
CN112133369B (zh) * 2020-08-26 2023-09-22 吴安华 基于活性氧评估肿瘤患者预后性的系统以及药物敏感性评价与改善方法
CN116926198A (zh) * 2023-09-15 2023-10-24 臻和(北京)生物科技有限公司 检测胃癌组织Claudin18.2蛋白阳性的方法、装置、设备和存储介质
CN117701719A (zh) * 2024-02-04 2024-03-15 北京肿瘤医院(北京大学肿瘤医院) 肿瘤靶向cldn18.2治疗耐药标志物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
NZ581541A (en) 2002-10-17 2011-07-29 Genmab As Human monoclonal antibodies against CD20
US20130236449A1 (en) * 2010-04-21 2013-09-12 Ventirx Pharmaceuticals, Inc. Methods of enhancing antibody-dependent cellular cytotoxicity
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014146672A1 (fr) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
WO2016165765A1 (fr) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer

Also Published As

Publication number Publication date
BR112017018775A2 (pt) 2018-04-17
IL296503B2 (en) 2024-02-01
KR102409933B1 (ko) 2022-06-17
IL305880A (en) 2023-11-01
JP2022023226A (ja) 2022-02-07
WO2016165765A1 (fr) 2016-10-20
US20180073077A1 (en) 2018-03-15
JP2018512146A (ja) 2018-05-17
AU2016249784A1 (en) 2017-11-02
EP3283644B1 (fr) 2020-04-01
ZA201705936B (en) 2019-06-26
RU2017139489A3 (fr) 2019-11-18
JP7217327B2 (ja) 2023-02-02
CA2982390A1 (fr) 2016-10-20
IL254086B2 (en) 2023-04-01
KR20170138431A (ko) 2017-12-15
US10927413B2 (en) 2021-02-23
SG11201708270YA (en) 2017-11-29
US20240110247A1 (en) 2024-04-04
NZ736368A (en) 2021-09-24
WO2016166124A1 (fr) 2016-10-20
IL296503B1 (en) 2023-10-01
MX2017013074A (es) 2018-03-15
RU2017139489A (ru) 2019-05-15
IL296503A (en) 2022-11-01
US20210324472A1 (en) 2021-10-21
IL254086A0 (en) 2017-10-31
HK1246829A1 (zh) 2018-09-14
US11732308B2 (en) 2023-08-22
EP3283644A1 (fr) 2018-02-21
IL254086B (en) 2022-12-01
KR20220086708A (ko) 2022-06-23
JP2023040269A (ja) 2023-03-22
ES2787708T3 (es) 2020-10-16
MX2021013938A (es) 2022-01-04
CN107873061B (zh) 2022-09-13
AU2016249784B2 (en) 2021-03-11
JP6976855B2 (ja) 2021-12-08
CN107873061A (zh) 2018-04-03

Similar Documents

Publication Publication Date Title
MA42974A (fr) Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer
IL267247B (en) Compositions and methods for treating cancer
HK1247093A1 (zh) 使用納米顆粒mtor抑制劑聯合療法治療實體瘤的方法
HK1253093A1 (zh) 診斷和治療癌症的方法
HK1232141A1 (zh) 用於治療亨廷頓病的方法和組合物
HK1213189A1 (zh) 預防腫瘤轉移、癌症治療和預後及鑒定為推定轉移抑制劑的試劑的方法
IL249658A0 (en) Methods of treating cancer using tigit inhibitors and anticancer agents
MA43283A (fr) Procédés et compositions pour le traitement du cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
HK1248602A1 (zh) 治療癌症的組合物及方法
HK1247630A1 (zh) 用於增强癌症治療的效果的組合物和方法
MA47613A (fr) Compositions et procédés de traitement du cancer
PT3200815T (pt) Métodos e composições para o tratamento de cancro
ZA201900960B (en) Methods and compositions for the treatment of cancer
EP3126525A4 (fr) Procédé et kits d'identification d'inhibiteurs de cdk9 pour le traitement du cancer
IL254842B (en) Therapeutic preparations and methods for use in cancer treatment
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
IL257670A (en) Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
ZA201808232B (en) Compositions and methods for the treatment of cancer
HK1250958A1 (zh) 用於治療癌症的組合物和方法
MA43426A (fr) Compositions et procédés permettant d'administrer des agents thérapeutiques
GB201418640D0 (en) Agents and methods for treatment of cancer
TH1501005132A (th) องค์ประกอบ และวิธีการสำหรับการวินิจฉัย และการรักษามะเร็งตับ